R&D News | pharmaphorum

News

Allergan abandons women’s health sale plan as profit slumps

Shares in Allergan fell after the company said it had swung to a loss in the last quarter of 2018, and forecast 2019 revenues below analyst expectations.

News

Illustration of a nerve cell on a colored background with light effects

Mixed results for non-opioid pain drug from Pfizer/Lilly

Pfizer and Eli Lilly have produced more phase 3 data that appear to back their non-opioid painkiller tanezumab.

News

Roche cancels two phase III Alzheimer’s trials

Roche and AC Immune have discontinued phase III trials of their Alzheimer’s disease drug crenezumab after an interim analysis indicated it would not hit its primary endpoint.

News

AbbVie and J&J claim new Imbruvica okay in US

AbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukaemia (CLL) to be approved by the FDA, its tenth indication.

News

AbbVie wobbles as biosimilars bite Humira

AbbVie’s shares slipped ahead of the weekend when its fourth-quarter revenues missed forecasts, after biosimilar competition – particularly in Europe – weakened cash cow product Humira.

News